Spherix Incorporated - Product Pipeline Review - 2012 - This pharmaceuticals report, "Spherix Incorporated - Product Pipeline Review - 2012" provides data on the Spherix Incorporated's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Spherix Incorporated's corporate website, SEC filings, investor presentations and featured press releases, both from Spherix Incorporated and industry-specific third party sources, put together by This team.
Scope
- Spherix Incorporated - Brief Spherix Incorporated overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Spherix Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Spherix Incorporated with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Spherix Incorporated's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Spherix Incorporated's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Spherix Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Spherix Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Spherix Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Spherix Incorporated and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Spherix Incorporated; Spherix Incorporated - Key Therapeutics; Spherix Incorporated - Pipeline Overview and Promising Molecules; Spherix Incorporated - News; Spherix Incorporated - Latest Updates; Spherix Incorporated - Pipeline; Spherix Incorporated - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Spherix Incorporated Snapshot
Spherix Incorporated Overview
Key Information
Key Facts
Spherix Incorporated - Research and Development Overview
Key Therapeutic Areas
Spherix Incorporated - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Spherix Incorporated - Pipeline Products Glance
Spherix Incorporated - Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Spherix Incorporated Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Spherix Incorporated - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Spherix Incorporated - Drug Profiles
Naturlose
Product Description
Mechanism of Action
R&D Progress
SPX 10624258
Product Description
Mechanism of Action
R&D Progress
SPX 7233801
Product Description
Mechanism of Action
R&D Progress
SPX 8522876
Product Description
Mechanism of Action
R&D Progress
SPX 8818309
Product Description
Mechanism of Action
R&D Progress
SPX 8818440
Product Description
Mechanism of Action
R&D Progress
SPX-106 + D-Tagatose
Product Description
Mechanism of Action
R&D Progress
Spherix Incorporated - Pipeline Products by Route of Administration
Spherix Incorporated - Pipeline Products By Mechanism of Action
Spherix Incorporated - Recent Pipeline Updates
Spherix Incorporated - Company Statement
Spherix Incorporated - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Spherix Incorporated, Recent Developments
Spherix Incorporated- Press Release
Jun 27, 2012: Spherix Reports Findings From New Study In Mice Showing SPX106T Yields Significant Reductions In Serum VLDL
Mar 07, 2012: Spherix's SPX-106T Arrests Development Of Atheroschlerotic Plaques In Mouse Model Of Cardiovascular Disease
Jan 11, 2012: Spherix Announces Successful Completion Of Toxicology Study Of SPX-106
Nov 16, 2009: Spherix Announces Positive Interim Results In Phase 3 Trial Of Novel, Oral Compound For Type 2 Diabetes
Jun 24, 2009: Spherix Announces Positive Phase 2 Study Results
Financial Deals Landscape
Spherix Incorporated, Deals Summary
Spherix Incorporated, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Biospherics Enters Into Licensing Agreement With University Of Kentucky Research Foundation
Equity Offering
Spherix Completes Private Placement Of Units For $1.2 Million
Spherix Completes Private Placement Of Common Stock For $1.3 Million
Spherix Completes Registered Direct Offering Of Units For $3 Million
Spherix Completes Private Placement Of Series B Convertible Preferred Stock For $5 Million
Spherix Completes Registered Direct Offering Of $6.3 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Spherix Incorporated, Key Information
Spherix Incorporated, Key Facts
Spherix Incorporated - Pipeline by Indication, 2012
Spherix Incorporated - Pipeline by Stage of Development, 2012
Spherix Incorporated - Monotherapy Products in Pipeline, 2012
Spherix Incorporated - Combination Treatment Modalities in Pipeline, 2012
Spherix Incorporated - Phase III, 2012
Spherix Incorporated - Phase I, 2012
Spherix Incorporated - Pre-Clinical, 2012
Spherix Incorporated - Pipeline By Route of Administration, 2012
Spherix Incorporated - Pipeline Products By Mechanism of Action, 2012
Spherix Incorporated - Recent Pipeline Updates, 2012
Spherix Incorporated, Subsidiaries
Spherix Incorporated, Deals Summary
Biospherics Enters Into Licensing Agreement With University Of Kentucky Research Foundation
Spherix Completes Private Placement Of Units For $1.2 Million
Spherix Completes Private Placement Of Common Stock For $1.3 Million
Spherix Completes Registered Direct Offering Of Units For $3 Million
Spherix Completes Private Placement Of Series B Convertible Preferred Stock For $5 Million
Spherix Completes Registered Direct Offering Of $6.3 Million
List of Figures
Spherix Incorporated - Pipeline by Indication, 2012
Spherix Incorporated - Pipeline by Stage of Development, 2012
Spherix Incorporated - Monotherapy Products in Pipeline, 2012
Spherix Incorporated - Combination Treatment Modalities in Pipeline, 2012
Spherix Incorporated - Pipeline Products By Mechanism of Action, 2012 23